- Home
- DMAC vs DDD Comparison
DMAC vs DDD Comparison
Compare DMAC & DDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- DDD
- Stock Information
- Founded
- DMAC 2000
- DDD 1986
- Country
- DMAC United States
- DDD United States
- Employees
- DMAC N/A
- DDD N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- DDD Computer peripheral equipment
- Sector
- DMAC Health Care
- DDD Technology
- Exchange
- DMAC Nasdaq
- DDD Nasdaq
- Market Cap
- DMAC 310.1M
- DDD 360.4M
- IPO Year
- DMAC N/A
- DDD N/A
- Fundamental
- Price
- DMAC $6.96
- DDD $3.25
- Analyst Decision
- DMAC Strong Buy
- DDD Buy
- Analyst Count
- DMAC 3
- DDD 2
- Target Price
- DMAC $12.33
- DDD $5.00
- AVG Volume (30 Days)
- DMAC 343.5K
- DDD 4.5M
- Earning Date
- DMAC 11-12-2025
- DDD 11-25-2025
- Dividend Yield
- DMAC N/A
- DDD N/A
- EPS Growth
- DMAC N/A
- DDD N/A
- EPS
- DMAC N/A
- DDD N/A
- Revenue
- DMAC N/A
- DDD $413,342,000.00
- Revenue This Year
- DMAC N/A
- DDD N/A
- Revenue Next Year
- DMAC N/A
- DDD $1.78
- P/E Ratio
- DMAC N/A
- DDD N/A
- Revenue Growth
- DMAC N/A
- DDD N/A
- 52 Week Low
- DMAC $3.19
- DDD $1.32
- 52 Week High
- DMAC $7.49
- DDD $5.00
- Technical
- Relative Strength Index (RSI)
- DMAC 58.60
- DDD 71.20
- Support Level
- DMAC $6.75
- DDD $2.80
- Resistance Level
- DMAC $7.13
- DDD $3.54
- Average True Range (ATR)
- DMAC 0.28
- DDD 0.25
- MACD
- DMAC -0.06
- DDD 0.02
- Stochastic Oscillator
- DMAC 50.00
- DDD 68.13
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About DDD 3D Systems Corporation
3D Systems Corp provides comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, advanced manufacturing and applications engineering. The company's segments include Healthcare Solutions and Industrial Solutions. It generates maximum revenue from the Industrial segment. It conducts business through various offices and facilities located throughout the Americas, EMEA, and APAC; generating a vast majority of revenues from the Americas.